SAB Biotherapeutics, Inc.

SABS Nasdaq SEC CIK 1833214
Follow SAB Biotherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$22.3M
EPS, diluted −$0.24 −148% vs same quarter last year
Operating cash flow −$13M +0.2% vs same quarter last year
Operating income −$25.9M −104.3% vs same quarter last year
Net income by quarter
−$11.4M
−$5.2M
−$10.1M
−$16.9M
−$18.9M
−$22.5M
−$22.3M
Q4 24 Q1 25 Q2 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$50M$0$50M$100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$0-
FY24$1.3M−$34.1M
FY23$2.2M−$42.2M
FY22$23.9M−$18.7M
FY21$60.9M−$17.1M
FY20$55.2M$20.1M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%1000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24−3244.9%−2579%
FY23−1700.6%−1884.5%
FY22−121%−78.4%
FY21−22%−28.2%
FY2037.2%36.4%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$45.7M
FY24−$34.6M
FY23−$25.3M
FY22−$25.6M
FY21−$9M
FY20−$2.7M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • SAB Biotherapeutics
  • Healthcare median
−3000%−2000%−1000%0%1000%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearSAB BiotherapeuticsHealthcare median
FY25-−30.6%
FY24−2579%−47%
FY23−1884.5%−58%
FY22−78.4%−80.4%
FY21−28.2%−71.8%
FY2036.4%−62.2%
FY19-−46.2%